Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder - Slideshow

🇺🇸 Seeking Alpha (US) — 2026-08-12

Definium Therapeutics announced topline results from its Phase 3 Voyage study evaluating DT120 for Generalized Anxiety Disorder. The update provides early insights into the drug's efficacy and safety profile.

Markets Health Definium Therapeutics Phase 3 Voyage study DT120 Generalized Anxiety Disorder clinical trial

Read original source →

UK closes 13 more asylum hotels
Punch Nigeria — 2026-08-12
EFCC probe forces 24 oil firms to pay N115bn, $84m NDDC levies
Punch Nigeria — 2026-08-12
Kushner, Iger Buy Lakers for Record-Breaking $12.5 Billion
Bloomberg — 2026-08-12
Bitcoin unable to shake off the doldrums even as Fed rate hike bets pared
Investing.com — 2026-08-12
Indonesian Tech Firm GoTo Cut From MSCI Indexes in Review
Bloomberg — 2026-08-12
US stocks mostly up after data shows slightly lower inflation in July
Channel NewsAsia — 2026-08-12

Definium Therapeutics, Inc. (DFTX) Discusses Phase 3 Voyage Study Topline Results for DT120 in Generalized Anxiety Disorder - Slideshow

AI Summary

Related Articles

UK closes 13 more asylum hotels

EFCC probe forces 24 oil firms to pay N115bn, $84m NDDC levies

Kushner, Iger Buy Lakers for Record-Breaking $12.5 Billion

Bitcoin unable to shake off the doldrums even as Fed rate hike bets pared

Indonesian Tech Firm GoTo Cut From MSCI Indexes in Review

US stocks mostly up after data shows slightly lower inflation in July